clinical trial · NCT05979051
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
Guangdong Hengrui Pharmaceutical Co., Ltd·phase3·recruiting·n = 166
Eosinophilic Granulomatosis With PolyangiitisSHR-1703Mepolizumab Injection
brief summary
This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.
started
Nov 16, 2023
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Dec 4, 2025
official title
A Multicenter, Single-arm/Randomized, Double-blind, Active-controlled, Parallel-group Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR-1703 for Patients With EGPA
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol